• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    TNF Pharmaceuticals Announces Closing of $7 Million Private Placement

    9/4/25 9:15:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $TNFA alert in real time by email

    Financing priced at a 44% premium to market

    Led by a top strategic investor with significant participation from existing stockholders

    TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company") today announced the closing of a $7.0 million private placement financing of convertible preferred stock with the Company's largest strategic stockholder and other existing stockholders.

    The private placement involved the sale of 7,000 shares of preferred stock, with a stated value of $1,000 per share, convertible into 1,400,000 million shares of the Company's common stock at an initial conversion price of $5.00, and accompanying warrants to purchase up to 1,400,000 shares of the Company's common stock at a conversion price of $5.00. The shares of preferred stock and the warrants will not be convertible or exercisable, respectively, until receipt of the requisite stockholder approval. Aggregate gross proceeds from the private placement totaled $7 million.

    "We appreciate the vote of confidence in TNF's value proposition and execution of our newest strategies," said Joshua Silverman, TNF's Executive Chairman. "We believe the $7 million in new capital positions TNF to complete key development milestones planned for our newly licensed innovative technology, which we believe is the first light-based computing accelerator for blockchain."

    As of September 3, 2025, TNF's shares of common stock outstanding totaled 1,846,930.

    "We are actively engaging strategic opportunities to continue the development of isomyosamine and Supera-CBD," said Mitchell Glass, Chief Medical Officer. "Our goal is to ensure these assets continue to create value for shareholders."

    The securities in the private placement were offered and sold in transactions exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions under applicable state laws.

    This press release is not an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    Rodman & Renshaw, LLC, H.C. Wainwright & Co. and GP Nurmenkari Inc. (GPN) acted as placement agents on the transaction.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as "anticipate," "believe," "could," "estimate," "expect," "may," "plan," "will," "would'' and other similar expressions are intended to identify these forward-looking statements and include statements related to the expected benefits from the licensing agreement with LightSolver and performance of LightSolver's technology. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions, the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250904261260/en/

    Investor Contact:

    tnfpharma.com/contact

    Get the next $TNFA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TNFA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TNFA
    SEC Filings

    View All

    TNF Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    9/26/25 5:10:36 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

    9/10/25 5:00:34 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: TNF Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

    9/5/25 5:30:47 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TNFA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Vice President, Finance Rauch Gary M

    4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/18/25 4:30:15 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by President, CMO Glass Mitchell

    4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/18/25 4:30:12 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Interim CFO Rhodes Ian

    4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/18/25 4:30:14 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TNFA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"

    Licensed technology positions Company at forefront of new quantum-class computing paradigm Q/C Technologies, Inc. (NASDAQ:QCLS), formerly TNF Pharmaceuticals, Inc. (NASDAQ: TNFA), ("Q/C" or "the Company"), today announced that its common stock will begin trading under the new ticker symbol "QCLS" beginning today at the market open. The Company's new name Q/C Technologies represents its recent strategic pivot into quantum-class computing with exclusive global rights to LightSolver's light-speed laser processing unit (LPU), the world's first light and laser-based computing system, for application in quantum class cryptocurrency verticals. "The official transition to Q/C Technologies and

    9/25/25 9:15:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol "QCLS" to Reflect Strategic Focus on Quantum Class Photonic Computing

    New trading symbol QCLS effective Thursday, September 25, 2025 Licensed technology positions Company at forefront of new quantum-class computing paradigm TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("Q/C" or the "Company") today announced that it has changed its corporate name to Q/C Technologies, Inc. and will begin trading under the new ticker symbol "QCLS" on the Nasdaq Capital Market, effective as of the market open on Thursday, September 25, 2025. Until then, the Company's common stock will continue to trade under its current ticker symbol "TNFA." The new name Q/C Technologies represents the Company's recent strategic pivot into quantum-class computing with exclusive global rights to

    9/24/25 9:15:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

    TNF Pharmaceuticals Inc. (NASDAQ:TNFA), ("TNF" or the "Company") today announced that it received written notice from the Nasdaq Stock Market on September 16, 2025, confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2). To regain compliance with the Listing Rule, the Company's shares maintained the minimum bid price of $1.00 for 10 consecutive business days. "We are pleased to have regained compliance with Nasdaq's listing standards. This milestone comes as we work to build a strong strategic platform for growth and shareholder value. We will be updating shareholders on our progress in the weeks ahead,"

    9/17/25 9:24:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TNFA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TNF Pharmaceuticals Inc.

    SC 13G/A - TNF Pharmaceuticals, Inc. (0001321834) (Subject)

    11/14/24 2:24:58 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TNFA
    Financials

    Live finance-specific insights

    View All

    TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

    Concurrent clinical studies underway evaluating novel TNF-alpha inhibitor for treating muscle loss associated with hip/femur fracture repair, GLP-1 weight loss Investors invited to submit questions prior to the event TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it will host an investor conference call and webcast on Thursday, March 6, 2025, at 4:30 pm ET. Mitchell Glass, M.D., President and Chief Medical Officer of TNF, will provide a clinical scientific update on the Company's lead candidate isomyosamine, a novel oral TNF

    3/5/25 9:00:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care